Vartanian TK - Search Results

1

The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists.

Fox EJ, Vartanian TK, Zamvil SS. Fox EJ, et al. Among authors: vartanian tk. Neurologist. 2007 Nov;13(6):355-62. doi: 10.1097/NRL.0b013e318148c08e. Neurologist. 2007. PMID: 18090713 Review.

2

Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis.

Vartanian TK, Zamvil SS, Fox E, Sorensen PS. Vartanian TK, et al. Neurology. 2004 Dec 14;63(11 Suppl 5):S42-9. doi: 10.1212/wnl.63.11_suppl_5.s42. Neurology. 2004. PMID: 15596736 Review.

3

Relapses in multiple sclerosis: Relationship to disability.

Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D, Racke MK, Trapp BD, Vartanian T, Waubant E. Goodin DS, et al. Mult Scler Relat Disord. 2016 Mar;6:10-20. doi: 10.1016/j.msard.2015.09.002. Epub 2015 Sep 8. Mult Scler Relat Disord. 2016. PMID: 27063617 Review.

4

Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.

Vartanian T, Sölberg Sørensen P, Rice G. Vartanian T, et al. J Neurol. 2004 Jun;251 Suppl 2:II25-30. doi: 10.1007/s00415-004-1205-6. J Neurol. 2004. PMID: 15264109

5

An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis.

Vartanian T. Vartanian T. Clin Ther. 2003 Jan;25(1):105-18. doi: 10.1016/s0149-2918(03)90013-0. Clin Ther. 2003. PMID: 12637114 Review.

6

Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.

Kaunzner UW, Kang Y, Monohan E, Kothari PJ, Nealon N, Perumal J, Vartanian T, Kuceyeski A, Vallabhajosula S, Mozley PD, Riley CS, Newman SM, Gauthier SA. Kaunzner UW, et al. Mult Scler Relat Disord. 2017 Jul;15:27-33. doi: 10.1016/j.msard.2017.04.008. Epub 2017 Apr 29. Mult Scler Relat Disord. 2017. PMID: 28641769

7

Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.

Ranganathan U, Kaunzner U, Foster S, Vartanian T, Perumal JS. Ranganathan U, et al. Mult Scler. 2018 Apr;24(4):540-542. doi: 10.1177/1352458517699876. Epub 2017 Mar 13. Mult Scler. 2018. PMID: 28287030

8

Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.

Ranganathan U, Kaunzner U, Foster S, Vartanian T, Perumal JS. Ranganathan U, et al. Mult Scler. 2018 Apr;24(4):553-554. doi: 10.1177/1352458517719152. Epub 2017 Jun 29. Mult Scler. 2018. PMID: 28661221 No abstract available.

9

Differential Impact of Multiple Sclerosis on Cortical and Deep Gray Matter Structures in African Americans and Caucasian Americans.

Al-Kawaz M, Monohan E, Morris E, Perumal JS, Nealon N, Vartanian T, Gauthier SA. Al-Kawaz M, et al. J Neuroimaging. 2017 May;27(3):333-338. doi: 10.1111/jon.12393. Epub 2016 Sep 16. J Neuroimaging. 2017. PMID: 27634620

10

Measuring longitudinal myelin water fraction in new multiple sclerosis lesions.

Vargas WS, Monohan E, Pandya S, Raj A, Vartanian T, Nguyen TD, Hurtado Rúa SM, Gauthier SA. Vargas WS, et al. Neuroimage Clin. 2015 Sep 12;9:369-75. doi: 10.1016/j.nicl.2015.09.003. eCollection 2015. Neuroimage Clin. 2015. PMID: 26594620 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page